Kronos Bio Inc Asset Resilience Ratio
Kronos Bio Inc asset resilience ratio. Kronos Bio Inc (KRON) has an Asset Resilience Ratio of 7.54% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kronos Bio Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kronos Bio Inc (2018–2024)
Asset resilience ratio of Kronos Bio Inc from 2018 to 2024. This chart shows how Kronos Bio Inc's Asset Resilience Ratio has changed over time. Read Kronos Bio Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kronos Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KRON current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.16 Million | 7.54% |
| Total Liquid Assets | $8.16 Million | 7.54% |
Asset Resilience Insights
- Limited Liquidity: Kronos Bio Inc maintains only 7.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Kronos Bio Inc Industry Peers by Asset Resilience Ratio
Compare Kronos Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Kronos Bio Inc Asset Resilience Ratio by Year (2018–2024)
Kronos Bio Inc asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for Kronos Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 22.39% | $27.85 Million | $124.36 Million | -28.56pp |
| 2023-12-31 | 50.95% | $108.67 Million | $213.28 Million | -4.05pp |
| 2022-12-31 | 55.00% | $162.21 Million | $294.94 Million | +18.92pp |
| 2021-12-31 | 36.08% | $141.24 Million | $391.48 Million | +3.84pp |
| 2020-12-31 | 32.24% | $165.05 Million | $511.96 Million | -25.82pp |
| 2019-12-31 | 58.05% | $59.61 Million | $102.69 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $12.61 Million | -- |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more